Study #2021-0589
Strategic Alliance: A Phase II clinical trial to evaluate safety and efficacy of XmAb20717 in advanced rare cancers
MD Anderson Study Status
Not Accepting
Treatment Agent
XmAb20717
Description
To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade, Neuroendocrine Carcinomas, Cervical Carcinoma, Hodgkin's Lymphoma, Pleural Mesothelioma, Small Cell Lung Cancer
Study phase:
Phase II
Physician name:
Arvind Nageshwara Vijaya Dasari
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.